Description of Liraglutide CAS 204656-20-2

 Introduction for  Liraglutide CAS 204656-20-2
Liraglutide (NN2211) is a long-acting gluca on-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
Liraglutide was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010. More recently, Liraglutide was approved by the FDA on December 23, 2014 for treatment for obesity in adults with some related comorbidity.

FUNCTION

Liraglutide is a once-daily injectable derivative of the human incretin glucagon-like peptide-1 (GLP-1), for the treatment of type
2 diabetes or obesity.

APPLICATION

1.Treating type 2 diabetes.
2.Treating obesity.

1. Glutamine Powder is the most prevalent amino acid in the bloodstream.

2. Glutamine Powder is involved in more metabolic processes than any other amino acid.

3. Glutamine Powder is converted to glucose when more glucose is required by the body as an energy source.

4. Glutamine Powder also plays a part in maintaining proper blood glucose levels and the right pH range.

5. Glutamine Powder serves as a source of fuel for cells lining the intestines. Without it, these cells waste away.

6. Glutamine Powder assists in maintaining the proper acid/alkaline balance in the body, and is the basis of the building
blocks for the synthesis of RNA and DNA.

TOP Purity MASTERONE Raw Powder for Bodybuiler Supplement

Drostanolon'e Enanthat'e
CAS NO:47'2-6'1-1'4'5
Appearance: White crystalline powder 
Uses: pharmaceutical raw materials, the hormones
Package: 500G/bag 
Assay: 99%